Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Survivor: Novo Nordisk Sets Levemir Apart Amid Synthetic Insulin Scare

Executive Summary

There will be winners and losers for the makers of type 2 diabetes drugs as doctors and patients absorb news of a potentially higher cancer risk for Sanofi-Aventis' long-acting insulin Lantus. Not surprisingly, Novo Nordisk is working hard to come out on top in any shakeout and held a recent presentation to make its case to investors
Advertisement

Related Content

Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
Novo Disappoints With No Liraglutide News, But Growth Is Strong
Will Sanofi's Lantus Survive Cancer Scare? Studies Suggest a Worrisome Link
GSK Stands By Avandia: Seeks Label Change, Asks Docs To Give It Another Try
Novo Nordisk’s Liraglutide Adds Thyroid Cancer Risk To The Diabetes Safety Gauntlet

Topics

Advertisement
UsernamePublicRestriction

Register

PS051250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel